+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Dementia and Movement Disorder Treatment Market

  • PDF Icon

    Report

  • 120 Pages
  • May 2022
  • Region: Global
  • TechNavio
  • ID: 5591861
1h Free Analyst Time

The market is driven by the growing geriatric population, the rising prevalence of target diseases, and the emergence of strategies to increase public awareness

1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Technavio has been monitoring dementia and movement disorder treatment market is poised to grow by $7.14 billion during 2022-2026, accelerating at a CAGR of 6.95% during the forecast period.

This report on the dementia and movement disorder treatment market provides a holistic analysis, of market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment.

The market is driven by the growing geriatric population, the rising prevalence of target diseases, and the emergence of strategies to increase public awareness.

Dementia and movement disorder treatment market analysis include class segment and geographic landscape.

The dementia and movement disorder treatment market is segmented as below:


By Drug Class

  • MAO inhibitors
  • Acetylcholinesterase inhibitors
  • Glutamate inhibitors
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the emergence of biomarkers as one of the prime reasons driving dementia and movement disorder treatment market growth during the next few years. Also, the growth of gene therapy to reverse cognitive decline associated with Alzheimer's disease and advances in biomedical science will lead to sizable demand in the market.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. This report covers the following areas:
  • Dementia and movement disorder treatment market sizing
  • Dementia and movement disorder treatment market forecast
  • Dementia and movement disorder treatment market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, the report provides a detailed analysis of several leading dementia and movement disorder treatment market vendors that include AbbVie Inc., Acorda Therapeutics Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Biogen Inc., Eisai Co. Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Kyowa Kirin Co. Ltd., Lannett Co. Inc., Merck and Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Organon and Co., Orion Pharma Ltd., Otsuka Holdings Co. Ltd., Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., UCB SA, and Vertical Pharmaceuticals LLC. Also, dementia and movement disorder treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The analyst's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 06: Executive Summary - Chart on Incremental Growth
Exhibit 07: Executive Summary - Data Table on Incremental Growth
Exhibit 08: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 09: Parent market
Exhibit 10: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
4.1 Five forces summary
Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
4.2 Bargaining power of buyers
Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
4.3 Bargaining power of suppliers
Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
4.4 Threat of new entrants
Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
4.5 Threat of substitutes
Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
4.6 Threat of rivalry
Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
4.7 Market condition
Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Drug Class
5.1 Market segments
Exhibit 24: Chart on Drug Class - Market share 2021-2026 (%)
Exhibit 25: Data Table on Drug Class - Market share 2021-2026 (%)
5.2 Comparison by Drug Class
Exhibit 26: Chart on Comparison by Drug Class
Exhibit 27: Data Table on Comparison by Drug Class
5.3 MAO inhibitors - Market size and forecast 2021-2026
Exhibit 28: Chart on MAO inhibitors - Market size and forecast 2021-2026 ($ million)
Exhibit 29: Data Table on MAO inhibitors - Market size and forecast 2021-2026 ($ million)
Exhibit 30: Chart on MAO inhibitors - Year-over-year growth 2021-2026 (%)
Exhibit 31: Data Table on MAO inhibitors - Year-over-year growth 2021-2026 (%)
5.4 Acetylcholinesterase inhibitors - Market size and forecast 2021-2026
Exhibit 32: Chart on Acetylcholinesterase inhibitors - Market size and forecast 2021-2026 ($ million)
Exhibit 33: Data Table on Acetylcholinesterase inhibitors - Market size and forecast 2021-2026 ($ million)
Exhibit 34: Chart on Acetylcholinesterase inhibitors - Year-over-year growth 2021-2026 (%)
Exhibit 35: Data Table on Acetylcholinesterase inhibitors - Year-over-year growth 2021-2026 (%)
5.5 Glutamate inhibitors - Market size and forecast 2021-2026
Exhibit 36: Chart on Glutamate inhibitors - Market size and forecast 2021-2026 ($ million)
Exhibit 37: Data Table on Glutamate inhibitors - Market size and forecast 2021-2026 ($ million)
Exhibit 38: Chart on Glutamate inhibitors - Year-over-year growth 2021-2026 (%)
Exhibit 39: Data Table on Glutamate inhibitors - Year-over-year growth 2021-2026 (%)
5.6 Others - Market size and forecast 2021-2026
Exhibit 40: Chart on Others - Market size and forecast 2021-2026 ($ million)
Exhibit 41: Data Table on Others - Market size and forecast 2021-2026 ($ million)
Exhibit 42: Chart on Others - Year-over-year growth 2021-2026 (%)
Exhibit 43: Data Table on Others - Year-over-year growth 2021-2026 (%)
5.7 Market opportunity by Drug Class
Exhibit 44: Market opportunity by Drug Class ($ million)
6 Customer Landscape
6.1 Customer landscape overview
Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
7.1 Geographic segmentation
Exhibit 46: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibit 47: Data Table on Market share By Geographical Landscape 2021-2026 (%)
7.2 Geographic comparison
Exhibit 48: Chart on Geographic comparison
Exhibit 49: Data Table on Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 54: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 55: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 56: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibit 57: Data Table on Europe - Year-over-year growth 2021-2026 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 58: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 59: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 60: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibit 61: Data Table on Asia - Year-over-year growth 2021-2026 (%)
7.6 Rest of World (ROW) - Market size and forecast 2021-2026
Exhibit 62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibit 65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
7.7 US - Market size and forecast 2021-2026
Exhibit 66: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibit 67: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibit 68: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibit 69: Data Table on US - Year-over-year growth 2021-2026 (%)
7.8 Germany - Market size and forecast 2021-2026
Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%)
7.9 UK - Market size and forecast 2021-2026
Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)
7.10 Canada - Market size and forecast 2021-2026
Exhibit 78: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 79: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 80: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibit 81: Data Table on Canada - Year-over-year growth 2021-2026 (%)
7.11 France - Market size and forecast 2021-2026
Exhibit 82: Chart on France - Market size and forecast 2021-2026 ($ million)
Exhibit 83: Data Table on France - Market size and forecast 2021-2026 ($ million)
Exhibit 84: Chart on France - Year-over-year growth 2021-2026 (%)
Exhibit 85: Data Table on France - Year-over-year growth 2021-2026 (%)
7.12 Market opportunity By Geographical Landscape
Exhibit 86: Market opportunity By Geographical Landscape ($ million)
8 Drivers, Challenges, and Trends
8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
Exhibit 87: Impact of drivers and challenges in 2021 and 2026
8.4 Market trends
9 Vendor Landscape
9.1 Overview
9.2 Vendor landscape
Exhibit 88: Overview on Criticality of inputs and Factors of differentiation
9.3 Landscape disruption
Exhibit 89: Overview on factors of disruption
9.4 Industry risks
Exhibit 90: Impact of key risks on business
10 Vendor Analysis
10.1 Vendors covered
Exhibit 91: Vendors covered
10.2 Market positioning of vendors
Exhibit 92: Matrix on vendor position and classification
10.3 AbbVie Inc.
Exhibit 93: AbbVie Inc. - Overview
Exhibit 94: AbbVie Inc. - Product / Service
Exhibit 95: AbbVie Inc. - Key offerings
10.4 Biogen Inc.
Exhibit 96: Biogen Inc. - Overview
Exhibit 97: Biogen Inc. - Product / Service
Exhibit 98: Biogen Inc. - Key offerings
10.5 Eisai Co. Ltd.
Exhibit 99: Eisai Co. Ltd. - Overview
Exhibit 100: Eisai Co. Ltd. - Business segments
Exhibit 101: Eisai Co. Ltd. - Key offerings
Exhibit 102: Eisai Co. Ltd. - Segment focus
10.6 H Lundbeck AS
Exhibit 103: H Lundbeck AS - Overview
Exhibit 104: H Lundbeck AS - Product / Service
Exhibit 105: H Lundbeck AS - Key offerings
10.7 Johnson and Johnson
Exhibit 106: Johnson and Johnson - Overview
Exhibit 107: Johnson and Johnson - Business segments
Exhibit 108: Johnson and Johnson - Key news
Exhibit 109: Johnson and Johnson - Key offerings
Exhibit 110: Johnson and Johnson - Segment focus
10.8 Merck and Co. Inc.
Exhibit 111: Merck and Co. Inc. - Overview
Exhibit 112: Merck and Co. Inc. - Business segments
Exhibit 113: Merck and Co. Inc. - Key news
Exhibit 114: Merck and Co. Inc. - Key offerings
Exhibit 115: Merck and Co. Inc. - Segment focus
10.9 Novartis AG
Exhibit 116: Novartis AG - Overview
Exhibit 117: Novartis AG - Business segments
Exhibit 118: Novartis AG - Key offerings
Exhibit 119: Novartis AG - Segment focus
10.10 Otsuka Holdings Co. Ltd.
Exhibit 120: Otsuka Holdings Co. Ltd. - Overview
Exhibit 121: Otsuka Holdings Co. Ltd. - Business segments
Exhibit 122: Otsuka Holdings Co. Ltd. - Key offerings
Exhibit 123: Otsuka Holdings Co. Ltd. - Segment focus
10.11 Teva Pharmaceutical Industries Ltd.
Exhibit 124: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 125: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 126: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 127: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 128: Teva Pharmaceutical Industries Ltd. - Segment focus
10.12 UCB SA
Exhibit 129: UCB SA - Overview
Exhibit 130: UCB SA - Product / Service
Exhibit 131: UCB SA - Key offerings
11 Appendix
11.1 Scope of the report
11.2 Inclusions and exclusions checklist
Exhibit 132: Inclusions checklist
Exhibit 133: Exclusions checklist
11.3 Currency conversion rates for US$
Exhibit 134: Currency conversion rates for US$
11.4 Research methodology
Exhibit 135: Research methodology
Exhibit 136: Validation techniques employed for market sizing
Exhibit 137: Information sources
11.5 List of abbreviations
Exhibit 138: List of abbreviations
List of Exhibits
Exhibit 1: Executive Summary - Chart on Market Overview
Exhibit 2: Executive Summary - Data Table on Market Overview
Exhibit 3: Executive Summary - Chart on Global Market Characteristics
Exhibit 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 5: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 6: Executive Summary - Chart on Incremental Growth
Exhibit 7: Executive Summary - Data Table on Incremental Growth
Exhibit 8: Executive Summary - Chart on Vendor Market Positioning
Exhibit 9: Parent market
Exhibit 10: Market Characteristics
Exhibit 11: Offerings of vendors included in the market definition
Exhibit 12: Market segments
Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
Exhibit 24: Chart on Drug Class - Market share 2021-2026 (%)
Exhibit 25: Data Table on Drug Class - Market share 2021-2026 (%)
Exhibit 26: Chart on Comparison by Drug Class
Exhibit 27: Data Table on Comparison by Drug Class
Exhibit 28: Chart on MAO inhibitors - Market size and forecast 2021-2026 ($ million)
Exhibit 29: Data Table on MAO inhibitors - Market size and forecast 2021-2026 ($ million)
Exhibit 30: Chart on MAO inhibitors - Year-over-year growth 2021-2026 (%)
Exhibit 31: Data Table on MAO inhibitors - Year-over-year growth 2021-2026 (%)
Exhibit 32: Chart on Acetylcholinesterase inhibitors - Market size and forecast 2021-2026 ($ million)
Exhibit 33: Data Table on Acetylcholinesterase inhibitors - Market size and forecast 2021-2026 ($ million)
Exhibit 34: Chart on Acetylcholinesterase inhibitors - Year-over-year growth 2021-2026 (%)
Exhibit 35: Data Table on Acetylcholinesterase inhibitors - Year-over-year growth 2021-2026 (%)
Exhibit 36: Chart on Glutamate inhibitors - Market size and forecast 2021-2026 ($ million)
Exhibit 37: Data Table on Glutamate inhibitors - Market size and forecast 2021-2026 ($ million)
Exhibit 38: Chart on Glutamate inhibitors - Year-over-year growth 2021-2026 (%)
Exhibit 39: Data Table on Glutamate inhibitors - Year-over-year growth 2021-2026 (%)
Exhibit 40: Chart on Others - Market size and forecast 2021-2026 ($ million)
Exhibit 41: Data Table on Others - Market size and forecast 2021-2026 ($ million)
Exhibit 42: Chart on Others - Year-over-year growth 2021-2026 (%)
Exhibit 43: Data Table on Others - Year-over-year growth 2021-2026 (%)
Exhibit 44: Market opportunity by Drug Class ($ million)
Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibit 46: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibit 47: Data Table on Market share By Geographical Landscape 2021-2026 (%)
Exhibit 48: Chart on Geographic comparison
Exhibit 49: Data Table on Geographic comparison
Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%)
Exhibit 54: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 55: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 56: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibit 57: Data Table on Europe - Year-over-year growth 2021-2026 (%)
Exhibit 58: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 59: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 60: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibit 61: Data Table on Asia - Year-over-year growth 2021-2026 (%)
Exhibit 62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibit 65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibit 66: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibit 67: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibit 68: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibit 69: Data Table on US - Year-over-year growth 2021-2026 (%)
Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%)
Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)
Exhibit 78: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 79: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 80: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibit 81: Data Table on Canada - Year-over-year growth 2021-2026 (%)
Exhibit 82: Chart on France - Market size and forecast 2021-2026 ($ million)
Exhibit 83: Data Table on France - Market size and forecast 2021-2026 ($ million)
Exhibit 84: Chart on France - Year-over-year growth 2021-2026 (%)
Exhibit 85: Data Table on France - Year-over-year growth 2021-2026 (%)
Exhibit 86: Market opportunity By Geographical Landscape ($ million)
Exhibit 87: Impact of drivers and challenges in 2021 and 2026
Exhibit 88: Overview on Criticality of inputs and Factors of differentiation
Exhibit 89: Overview on factors of disruption
Exhibit 90: Impact of key risks on business
Exhibit 91: Vendors covered
Exhibit 92: Matrix on vendor position and classification
Exhibit 93: AbbVie Inc. - Overview
Exhibit 94: AbbVie Inc. - Product / Service
Exhibit 95: AbbVie Inc. - Key offerings
Exhibit 96: Biogen Inc. - Overview
Exhibit 97: Biogen Inc. - Product / Service
Exhibit 98: Biogen Inc. - Key offerings
Exhibit 99: Eisai Co. Ltd. - Overview
Exhibit 100: Eisai Co. Ltd. - Business segments
Exhibit 101: Eisai Co. Ltd. - Key offerings
Exhibit 102: Eisai Co. Ltd. - Segment focus
Exhibit 103: H Lundbeck AS - Overview
Exhibit 104: H Lundbeck AS - Product / Service
Exhibit 105: H Lundbeck AS - Key offerings
Exhibit 106: Johnson and Johnson - Overview
Exhibit 107: Johnson and Johnson - Business segments
Exhibit 108: Johnson and Johnson - Key news
Exhibit 109: Johnson and Johnson - Key offerings
Exhibit 110: Johnson and Johnson - Segment focus
Exhibit 111: Merck and Co. Inc. - Overview
Exhibit 112: Merck and Co. Inc. - Business segments
Exhibit 113: Merck and Co. Inc. - Key news
Exhibit 114: Merck and Co. Inc. - Key offerings
Exhibit 115: Merck and Co. Inc. - Segment focus
Exhibit 116: Novartis AG - Overview
Exhibit 117: Novartis AG - Business segments
Exhibit 118: Novartis AG - Key offerings
Exhibit 119: Novartis AG - Segment focus
Exhibit 120: Otsuka Holdings Co. Ltd. - Overview
Exhibit 121: Otsuka Holdings Co. Ltd. - Business segments
Exhibit 122: Otsuka Holdings Co. Ltd. - Key offerings
Exhibit 123: Otsuka Holdings Co. Ltd. - Segment focus
Exhibit 124: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 125: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 126: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 127: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 128: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 129: UCB SA - Overview
Exhibit 130: UCB SA - Product / Service
Exhibit 131: UCB SA - Key offerings
Exhibit 132: Inclusions checklist
Exhibit 133: Exclusions checklist
Exhibit 134: Currency conversion rates for US$
Exhibit 135: Research methodology
Exhibit 136: Validation techniques employed for market sizing
Exhibit 137: Information sources
Exhibit 138: List of abbreviations

Executive Summary

The analyst recognizes the following companies as the key players in global dementia and movement disorder treatment market: AbbVie Inc., Acorda Therapeutics Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Biogen Inc., Eisai Co. Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Kyowa Kirin Co. Ltd., Lannett Co. Inc., Merck and Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Organon and Co., Orion Pharma Ltd., Otsuka Holdings Co. Ltd., Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., UCB SA, and Vertical Pharmaceuticals LLC.

Commenting on the report, an analyst said: ''The latest trend gaining momentum in the market is the emergence of biomarkers.''

According to the report, one of the major drivers for this market is the growing geriatric population.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • Acorda Therapeutics Inc.
  • Amneal Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • Biogen Inc.
  • Eisai Co. Ltd.
  • GlaxoSmithKline PLC
  • H Lundbeck AS
  • Johnson and Johnson
  • Kyowa Kirin Co. Ltd.
  • Lannett Co. Inc.
  • Merck and Co. Inc.
  • Neurocrine Biosciences Inc.
  • Novartis AG
  • Organon and Co.
  • Orion Pharma Ltd.
  • Otsuka Holdings Co. Ltd.
  • Supernus Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Vertical Pharmaceuticals LLC